Esther C.W. Breij

3.1k citations

60 papers · 2.2k indexed · h-index 21

Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment 7
Oncology top 5%
- CAR-T cell therapy research 11
- HER2/EGFR in Cancer Research 8
- Cancer Immunotherapy and Biomarkers 6
Hematology top 2%
Immunology top 5%
- Immunotherapy and Immune Responses 7
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 11
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 36
- Radiopharmaceutical Chemistry and Applications 5

Co-authors: Paul W.H.I. Parren Sandra Verploegen Christine D. Dijkstra Paul van der Valk Lars Bø Wim K. Bleeker Tuna Mutis Marije B. Overdijk
Cited by: Pathology and Forensic Medicine Oncology Hematology
Journals: Nature Medicine (1 paper)Journal of Clinical Oncology (2 papers)SHILAP Revista de lepidopterología (1 paper)
Partner nations: Netherlands United States Denmark

In The Last Decade

Esther C.W. Breij

57 papers receiving 2.1k citations

Peers

Countries citing papers authored by Esther C.W. Breij

Since Specialization

Citations

This map shows the geographic impact of Esther C.W. Breij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther C.W. Breij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther C.W. Breij more than expected).

Fields of papers citing papers by Esther C.W. Breij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther C.W. Breij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther C.W. Breij. The network helps show where Esther C.W. Breij may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Esther C.W. Breij, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Esther C.W. Breij Line = papers co-authored together Esther C.W. Breij links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1072P DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models Annals of Oncology ·Sina Fellermeier-Kopf,Andreea Ioan‐Facsinay,Andrea Imle,Annieck M. Diks,Kristina Nuermberger,Lars Guelen,Martin Köhne,Mischa Houtkamp,Aras Toker,Saskia M. Burm,Joshua T. Gamse,C. Janaitis,David Satijn,Alexander Muik,Tahamtan Ahmadi,Özlem Türeci,Kristel Kemper,Uğur Şahin,Esther C.W. Breij	2023	0
2	An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy Molecular Cancer Therapeutics ·Jantine E. Bakema,Marijke Stigter‐van Walsum,Jeffrey R. Harris,Sonja H. Ganzevles,Anantharaman Muthuswamy,Mischa Houtkamp,Theo S. Plantinga,Elisabeth Bloemena,Ruud H. Brakenhoff,Esther C.W. Breij,Rieneke van de Ven	2023	5
3	Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity EBioMedicine ·Ida H. Hiemstra,Kim C. M. Santegoets,Maarten L. Janmaat,Bart E.C.G. de Goeij,Wessel ten Hagen,Sanne van Dooremalen,Péter Boross,Jeroen van den Brakel,Sieto Bosgra,Grietje Andringa,Berris van Kessel-Welmers,Dennis Verzijl,Richard G. Hibbert,Kristine A. Frerichs,Tuna Mutis,Niels W.C.J. van de Donk,Tahamtan Ahmadi,David Satijn,A. Kate Sasser,Esther C.W. Breij	2023	18
4	Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting Blood Advances ·Maissa Mhibik,Erika M. Gaglione,David Eik,John H. Herrick,J. Le,Inhye E. Ahn,Christopher Chiu,Monica Wielgos-Bonvallet,Ida H. Hiemstra,Esther C.W. Breij,Jenny Chen,Edward B. Reilly,Pearlie K. Epling‐Burnette,Edith Szafer-Glusman,Clare Sun,Adrian Wiestner	2023	27
5	Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models Life Science Alliance ·Kristel Kemper,Ellis Gielen,Péter Boross,Mischa Houtkamp,Theo S. Plantinga,Stefanie AH de Poot,Saskia M. Burm,Maarten L. Janmaat,Louise A. Koopman,Edward N. van den Brink,Rik Rademaker,Dennis Verzijl,Patrick Engelberts,David Satijn,A. Kate Sasser,Esther C.W. Breij	2022	3
6	Systematic study of tissue factor expression in solid tumors Cancer Reports ·Johann S. de Bono,Jeffrey R. Harris,Saskia M. Burm,Adriaan Vanderstichele,Mischa Houtkamp,Saida Aarass,Ruth Riisnaes,Ines Figueiredo,Daniel Nava Rodrigues,Rossitza Christova,Siel Olbrecht,Hans W.M. Niessen,Sigrid R. Ruuls,Danita H. Schuurhuis,Jeroen J. Lammerts van Bueren,Esther C.W. Breij,Ignace Vergote	2022	19
7	PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS Hematological Oncology ·Christopher Chiu,Ida H. Hiemstra,Wessel ten Hagen,Rajaa Snijdewint-Nkairi,Bart de Jong,Patricia Garrido Castro,Christiaan Kweekel,Roberto S Oliveri,Baxter A. Elliot,M. Wielgos‐Bonvallet,Edith Szafer‐Glusman,Danita H. Schuurhuis,Julie Blædel,Tahamtan Ahmadi,Esther C.W. Breij,A. Kate Sasser,Maria Jure‐Kunkel	2021	1
8	Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment Blood Cancer Journal ·Hilma J. van der Horst,A. Vera de Jonge,Ida H. Hiemstra,Anne T. Gelderloos,Daniella R. A. I. Berry,Nathalie J. Hijmering,Hendrik F. van Essen,Daphne de Jong,Martine E.D. Chamuleau,Sonja Zweegman,Esther C.W. Breij,Margaretha G.M. Roemer,Tuna Mutis	2021	48
9	Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism Molecular Cancer Therapeutics ·Marije B. Overdijk,Kristin Strumane,Frank J. Beurskens,Antonio Ortiz Buijsse,Claudine Vermot‐Desroches,Boris Vuillermoz,Thessa Kroes,Bart de Jong,Naomi Hoevenaars,Richard G. Hibbert,Andreas Lingnau,Ulf Forssmann,Janine Schuurman,Paul W.H.I. Parren,Rob N. de Jong,Esther C.W. Breij	2020	36
10	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing EBioMedicine ·Patrick Engelberts,Ida H. Hiemstra,Bart de Jong,Danita H. Schuurhuis,Joyce Meesters,Irati Beltrán Hernández,Simone C. Oostindie,Joost Neijssen,Edward N. van den Brink,G. Jean Horbach,Sandra Verploegen,Aran F. Labrijn,Theodora W. Salcedo,Janine Schuurman,Paul W.H.I. Parren,Esther C.W. Breij	2020	102
11	DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies Blood Cancer Journal ·Simone C. Oostindie,Hilma J. van der Horst,Laurens P. Kil,Kristin Strumane,Marije B. Overdijk,Edward N. van den Brink,Jeroen H. N. van den Brakel,Hendrik J. Rademaker,Berris van Kessel,Juliette van den Noort,Martine E.D. Chamuleau,Tuna Mutis,Margaret A. Lindorfer,Ronald P. Taylor,Janine Schuurman,Paul W.H.I. Parren,Frank J. Beurskens,Esther C.W. Breij	2020	49
12	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer JCI Insight ·Louise A. Koopman,Mikkel G. Terp,Gijs G. Zom,Maarten L. Janmaat,Kirstine Jacobsen,Elke Gresnigt-van den Heuvel,Marcel Brandhorst,Ulf Forssmann,Freddy De Bree,Nora Pencheva,Andreas Lingnau,M Zipeto,Paul W.H.I. Parren,Esther C.W. Breij,Henrik J. Ditzel	2019	46
13	Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding Blood ·Hilma J. van der Horst,Marije B. Overdijk,Esther C.W. Breij,Martine E.D. Chamuleau,Henk M. Lokhorst,Tuna Mutis	2017	4
14	Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63 Molecular Cancer Therapeutics ·Bart E.C.G. de Goeij,Tom Vink,Hendrik ten Napel,Esther C.W. Breij,David Satijn,Richard Wubbolts,David Miao,Paul W.H.I. Parren	2016	101
15	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma mAbs ·Marije B. Overdijk,Sandra Verploegen,Marijn Bögels,Marjolein van Egmond,Jeroen J. Lammerts van Bueren,Tuna Mutis,Richard W.J. Groen,Esther C.W. Breij,Anton C. Martens,Wim K. Bleeker,Paul W.H.I. Parren	2015	370
16	An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors Cancer Research ·Esther C.W. Breij,Bart E.C.G. de Goeij,Sandra Verploegen,Danita H. Schuurhuis,Ali Amirkhosravi,John Francis,Vibeke Breinholt Miller,Mischa Houtkamp,Wim K. Bleeker,David Satijn,Paul W.H.I. Parren	2013	166
17	Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia Clinical Cancer Research ·Jacqueline M. Tromp,Christian R. Geest,Esther C.W. Breij,Judith A. Elias,Jacoline van Laar,Dieuwertje M. Luijks,Arnon P. Kater,Tim Beaumont,Marinus H. J. van Oers,Eric Eldering	2011	79
18	Homogeneity of active demyelinating lesions in established multiple sclerosis Annals of Neurology ·Esther C.W. Breij,Bianca P. Brink,Rob Veerhuis,Christa van den Berg,Rianka P. M. Vloet,Riqiang Yan,Christine D. Dijkstra,Paul van der Valk,Lars Bø	2008	255
19	The Pathology of Multiple Sclerosis Is Location-Dependent: No Significant Complement Activation Is Detected in Purely Cortical Lesions Journal of Neuropathology & Experimental Neurology ·Bianca P. Brink,Robert Veerhuis,Esther C.W. Breij,Paul van der Valk,Christine D. Dijkstra,Lars Bø	2005	149
20	Spatial structure, contrast polarity and motion integration Vision Research ·Maarten J. van der Smagt,Esther C.W. Breij,W. A. van de Grind	2000	2

About Esther C.W. Breij

Esther C.W. Breij is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology, having authored 60 papers that have together received 2.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (36 papers), Chronic Lymphocytic Leukemia Research (11 papers), CAR-T cell therapy research (11 papers), HER2/EGFR in Cancer Research (8 papers), Immunotherapy and Immune Responses (7 papers), Lymphoma Diagnosis and Treatment (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). The work is most often cited by research in Pathology and Forensic Medicine (663 citations), Oncology (921 citations) and Hematology (375 citations). Esther C.W. Breij has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Paul W.H.I. Parren, Sandra Verploegen, Christine D. Dijkstra, Paul van der Valk, Lars Bø, Wim K. Bleeker, Tuna Mutis, Marije B. Overdijk, David Satijn and Jeroen J. Lammerts van Bueren. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact